Kilitch Drugs (India) Ltd has announced the sale of its entire 100% stake in subsidiary Kilitch Estro Biotech PLC to Ethiopia's HarmeeCare Pharmaceuticals. The deal, valued at USD 12.85 million, includes a debt-to-equity conversion of Rs 57 crore. With the subsidiary accounting for over 20% of consolidated turnover, this divestment signals a major shift in the company’s international operations ahead of the January 2027 completion date.
Kilitch Drugs Approves Sale of Ethiopian Subsidiary
USD 12.85 Million consideration; 20.20% consolidated revenue contribution from divested unit.
Reader Takeaway: Divestment unlocks cash for the balance sheet but removes a significant contributor to the company’s total turnover.
What just happened
Kilitch Drugs (India) Ltd has approved the sale of its 100% shareholding in its Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB). The buyer, HarmeeCare Pharmaceuticals, a state-owned public enterprise in Ethiopia, will pay a total consideration of USD 14 million, with USD 12.85 million flowing directly to Kilitch Drugs. The transaction is expected to conclude by January 31, 2027.
Why this matters
KEB is a material subsidiary that contributed 20.20% to Kilitch Drugs’ consolidated turnover for FY 2025-26. The divestment will significantly alter the company's revenue composition. Furthermore, the company will convert Rs 57 crore of outstanding debt and service costs into equity in KEB before the final sale. This move is designed to clean up the balance sheet of the subsidiary and ensure regulatory compliance under FEMA guidelines.
Board and Governance Update
In addition to the divestment, the board has strengthened its governance by appointing Dr. Milind Kishor Madhani and Mr. Gautam Rajan as Additional Independent Directors for a five-year term, effective October 23, 2026. These appointments are subject to shareholder approval at an upcoming Extraordinary General Meeting (EGM).
Risks to watch
Investors should monitor the regulatory environment in Ethiopia and any potential delays in the 2027 transaction timeline. Given that a fifth of the company's revenue is currently tied to this asset, the loss of this stream will require management to demonstrate how they intend to offset the revenue gap and deploy the incoming cash to drive future growth.
What to track next
The final regulatory approvals for the transaction and the EGM outcomes regarding the new independent director appointments are the next key milestones for shareholders.